Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme

Endothelial dysfunction is the initial pathophysiological step in a progression of vascular damage that leads to overt cardiovascular and chronic kidney disease. Angiotensin II, the primary agent of the renin–angiotensin system (RAS), has a central role in endothelial dysfunction. Therefore, RAS blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruilope, Luis Miguel, Redón, Josep, Schmieder, Roland
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994043/
https://www.ncbi.nlm.nih.gov/pubmed/17583170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994043/
https://www.ncbi.nlm.nih.gov/pubmed/17583170

Ejemplares similares